Can Eli Lilly's (LLY) Growth Machine Keep Delivering?
Eli Lilly and Company (NYSE:LLY) has returned 36.37% over the last six months, as of October 15.
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 13,770 | $15,933,215 | +2% | 0.32% |
| 2. | Sivik Global Healthcare Krishen Sud | 4,230 | $4,894,448 | -16% | 2.8% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,175.10 | 6,500 | $7,638,150.00 | 54,147 | 2026-08-17 | Filing | |
| $1,185.01 | 2,000 | $2,370,020.00 | 1,526 | 2026-08-10 | Filing | |
| $1,190.00 | 5,000 | $5,950,000.00 | 11,875 | 2026-08-07 | Filing | |
| $1,150.77 | 2,500 | $2,876,925.00 | 29,804 | 2026-06-10 | Filing | |
| $996.18 | 2,208 | $2,199,572.06 | 91,881,150 | 2026-05-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,478,787 | $1,711,074,659 | 23.01% | |
| 2. | 784,936 | $908,233,747 | 0.88% | |
| 3. | 556,177 | $643,541,288 | 28.2% | |
| 4. | 411,540 | $476,184,703 | 41.31% | |
| 5. | 344,968 | $399,155,581 | 0.88% |
News See All
10 Best Stocks to Buy for the Next 20 Years
Buying a stock for the next 20 years requires looking beyond the next earnings report or market rally.
10 No-Brainer Stocks to Buy Now
Fed Chair Kevin Warsh gave no hint of another rate hike at an IMF event in Bangkok on October 16, and the odds of an October increase fell to roughly 15% on CME FedWatch, according to Benzinga on October...
Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
Eli Lilly and Company (NYSE:LLY) has become one of the pharmaceutical industry’s most important growth stories, but its valuation presents a harder question than whether demand for obesity treatments...
The Five Largest Holdings in the RANK ETF After Its Latest Rebalance
The Defiance KSM TipRanks Analyst ETF ($RANK) has completed its latest quarterly reconstitution and rebalance, which took effect after the close on...
Eli Lilly (LLY) Stock: Why Taking Profits Could Make Sense Ahead of 2027
Shares of drug maker Eli Lilly ($LLY) have modestly underperformed the S&P 500 ($SPY) in 2026, with large-cap U.S. stock returns increasingly drive...
Eli Lilly (LLY) Posted 48% Revenue Growth. Why Does the Stock Trade Below Its Average Multiple?
Eli Lilly (NYSE:LLY) reported 48% revenue growth for the second quarter of 2026 a while ago and raised its outlook for the year.
Alphabet’s AI Drug Hunter Isomorphic Labs In Fundraising Talks to Hit $40B Valuation
Alphabet ($GOOGL) company Isomorphic Labs is reportedly set to raise new funds, which would value it at around $40 billion. According to a Bloomber...
Eli Lilly (LLY) Has a Powerful Growth Flywheel Beyond Its GLP-1 Success
Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines
The World Health Organization (WHO) issued its first-ever guidelines on childhood and adolescent obesity on Wednesday. The guidelines discourage we...
Hedge Fund Resource Center